Sanofi (SNYNF) Return on Capital Employed (2018 - 2025)

Sanofi's (SNYNF) quarterly Return on Capital Employed came in at 6.1% in Q4 2025, down 23.7% quarter-over-quarter from 8.0% in Q2 2025.

Sanofi (SNYNF) Return on Capital Employed (2018 - 2025) Analysis & Trends

Sanofi has disclosed Return on Capital Employed across 2 years of filings, most recently posting 6.1% for Q4 2025.

Return on Capital Employed for Q4 2025 came in at 6.1%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 6.1% (changed N/A YoY), and the FY2025 annual result was 6.61%, down 56.0% from the prior year.
Return on Capital Employed came in at 6.1% for Q4 2025 at Sanofi, down from 8.0% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 8.0% in Q2 2025 to a low of 6.1% in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Gsk	96,436,181.12 Bn	96,436,176.16 Bn	7.76 Bn	9.49%
2	Eli Lilly	1,017.30 Bn	1,012.01 Bn	16.22 Bn	42.94%
3	Johnson & Johnson	579.61 Bn	557.55 Bn	15.96 Bn	28.18%
4	AbbVie	402.30 Bn	392.96 Bn	10.78 Bn	16.47%
5	Merck	294.24 Bn	288.59 Bn	12.09 Bn	-5.22%
6	Amgen	191.82 Bn	179.78 Bn	5.87 Bn	15.87%
7	Gilead Sciences	155.93 Bn	148.21 Bn	5.52 Bn	21.53%
8	Pfizer	149.05 Bn	136.28 Bn	-1.21 Bn	-10.20%
9	Bristol Myers Squibb	116.33 Bn	105.88 Bn	8.07 Bn	-6.84%
10	Sanofi	-	-	9.49 Bn	-

Download Data